1
|
Sirdah MM, Reading NS. Genetic predisposition in type 2 diabetes: A promising approach toward a personalized management of diabetes. Clin Genet 2020; 98:525-547. [PMID: 32385895 DOI: 10.1111/cge.13772] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2020] [Revised: 05/04/2020] [Accepted: 05/04/2020] [Indexed: 02/06/2023]
Abstract
Diabetes mellitus, also known simply as diabetes, has been described as a chronic and complex endocrine metabolic disorder that is a leading cause of death across the globe. It is considered a key public health problem worldwide and one of four important non-communicable diseases prioritized for intervention through world health campaigns by various international foundations. Among its four categories, Type 2 diabetes (T2D) is the commonest form of diabetes accounting for over 90% of worldwide cases. Unlike monogenic inherited disorders that are passed on in a simple pattern, T2D is a multifactorial disease with a complex etiology, where a mixture of genetic and environmental factors are strong candidates for the development of the clinical condition and pathology. The genetic factors are believed to be key predisposing determinants in individual susceptibility to T2D. Therefore, identifying the predisposing genetic variants could be a crucial step in T2D management as it may ameliorate the clinical condition and preclude complications. Through an understanding the unique genetic and environmental factors that influence the development of this chronic disease individuals can benefit from personalized approaches to treatment. We searched the literature published in three electronic databases: PubMed, Scopus and ISI Web of Science for the current status of T2D and its associated genetic risk variants and discus promising approaches toward a personalized management of this chronic, non-communicable disorder.
Collapse
Affiliation(s)
- Mahmoud M Sirdah
- Division of Hematology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.,Biology Department, Al Azhar University-Gaza, Gaza, Palestine
| | - N Scott Reading
- Institute for Clinical and Experimental Pathology, ARUP Laboratories, Salt Lake City, Utah, USA.,Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA
| |
Collapse
|
2
|
Role of PPARG (Pro12Ala) in Malaysian type 2 diabetes mellitus patients. Int J Diabetes Dev Ctries 2016. [DOI: 10.1007/s13410-015-0462-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
3
|
Senemar S, Edraki MR, Toosi S. Association between type 2 diabetes mellitus, biochemical factors and UCSNP-43 polymorphisms of CALPIN-10 gene in patients with atherosclerosis of coronary artery disease in Southern Iran population. J Cardiovasc Thorac Res 2016; 8:13-9. [PMID: 27069562 PMCID: PMC4827134 DOI: 10.15171/jcvtr.2016.03] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2015] [Accepted: 01/16/2016] [Indexed: 11/09/2022] Open
Abstract
Introduction: Genetic variations in the calpain 10 gene (CALPIN-10), single nucleotide polymorphisms-43 (SNP-43), have increased the risk of type 2 diabete mellitus (T2DM) and coronary artery disease (CAD).
Methods: We studied the control and CAD groups for association of association of SNP-43 in the CALPIN-10 gene with T2DM and other risk factors of its complications. Overall, we examined 452 individuals, 224 patients with CAD and 228 healthy subjects for CAD in Iranian population. All the subjects were genotyped for the CALPIN-10, SNP-43 by polymorphism chain reaction (PCR) and restriction fragment length polymorphism (RFLP) methods, using biochemical methods to detect fasting glucose and other biochemical factors in the blood sample. We assessed frequencies of SNP-43 alleles between CAD and normal population groups.
Results: In CAD patients, the GG allele was significantly associated with T2DM and GG allele was causing high level of glucose. But in control group, there was no relationship between them. Between clinical and biochemical risk factors with different genotypes there was no significant difference in the compared group.
Conclusion: The results of our study suggest no significant association between SNP-43 and the risk of T2DM. In other words, CALPIN-10 did not show a major diabetes gene pool capacity in normal southern Iranian population.
Collapse
Affiliation(s)
- Sara Senemar
- Human Genetics Research Group, Iranian Academic Center for Education & Research (ACECR), Fars Branch, Shiraz, Iran
| | - Mohammad Reza Edraki
- Institute for Pediatric Cardiologist, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Samane Toosi
- Human Genetics Research Group, Iranian Academic Center for Education & Research (ACECR), Fars Branch, Shiraz, Iran
| |
Collapse
|
4
|
Hua Y, Nair S. Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications. Biochim Biophys Acta Mol Basis Dis 2014; 1852:195-208. [PMID: 24815358 DOI: 10.1016/j.bbadis.2014.04.032] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Revised: 04/25/2014] [Accepted: 04/30/2014] [Indexed: 12/21/2022]
Abstract
Cardiovascular disease is the leading cause of death in the U.S. and other developed countries. Metabolic syndrome, including obesity, diabetes/insulin resistance, hypertension and dyslipidemia is a major threat for public health in the modern society. It is well established that metabolic syndrome contributes to the development of cardiovascular disease collective called as cardiometabolic disease. Despite documented studies in the research field of cardiometabolic disease, the underlying mechanisms are far from clear. Proteases are enzymes that break down proteins, many of which have been implicated in various diseases including cardiac disease. Matrix metalloproteinase (MMP), calpain, cathepsin and caspase are among the major proteases involved in cardiac remodeling. Recent studies have also implicated proteases in the pathogenesis of cardiometabolic disease. Elevated expression and activities of proteases in atherosclerosis, coronary heart disease, obesity/insulin-associated heart disease as well as hypertensive heart disease have been documented. Furthermore, transgenic animals that are deficient in or over-express proteases allow scientists to understand the causal relationship between proteases and cardiometabolic disease. Mechanistically, MMPs and cathepsins exert their effect on cardiometabolic diseases mainly through modifying the extracellular matrix. However, MMP and cathepsin are also reported to affect intracellular proteins, by which they contribute to the development of cardiometabolic diseases. On the other hand, activation of calpain and caspases has been shown to influence intracellular signaling cascade including the NF-κB and apoptosis pathways. Clinically, proteases are reported to function as biomarkers of cardiometabolic diseases. More importantly, the inhibitors of proteases are credited with beneficial cardiometabolic profile, although the exact molecular mechanisms underlying these salutary effects are still under investigation. A better understanding of the role of MMPs, cathepsins, calpains and caspases in cardiometabolic diseases process may yield novel therapeutic targets for treating or controlling these diseases. This article is part of a Special Issue entitled: Autophagy and protein quality control in cardiometabolic diseases.
Collapse
Affiliation(s)
- Yinan Hua
- Center for Cardiovascular Research and Alternative Medicine, University of Wyoming, School of Pharmacy, College of Health Sciences, Laramie, WY 82071, USA.
| | - Sreejayan Nair
- Center for Cardiovascular Research and Alternative Medicine, University of Wyoming, School of Pharmacy, College of Health Sciences, Laramie, WY 82071, USA.
| |
Collapse
|
5
|
Pánico P, Salazar AM, Burns AL, Ostrosky-Wegman P. Role of calpain-10 in the development of diabetes mellitus and its complications. Arch Med Res 2014; 45:103-15. [PMID: 24508288 DOI: 10.1016/j.arcmed.2014.01.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2013] [Accepted: 01/22/2014] [Indexed: 01/28/2023]
Abstract
Calpain activity has been implicated in several cellular processes such as cell signaling, apoptosis, exocytosis, mitochondrial metabolism and cytoskeletal remodeling. Evidence has indicated that the impairment of calpain expression and the activity of different calpain family members are involved in diverse pathologies. Calpain-10 has been implicated in the development of type 2 diabetes, and polymorphisms in the CAPN10 gene have been associated with an increased risk of developing this disease. The present work focused on the molecular biology of calpain-10, supporting its key participation in glucose metabolism. Current knowledge regarding the role of calpain-10 in the development of type 2 diabetes mellitus and diabetes-related diseases is additionally reviewed.
Collapse
Affiliation(s)
- Pablo Pánico
- Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), México, D.F. Mexico
| | - Ana María Salazar
- Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), México, D.F. Mexico
| | - Anna L Burns
- Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), México, D.F. Mexico
| | - Patricia Ostrosky-Wegman
- Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), México, D.F. Mexico.
| |
Collapse
|
6
|
Neuhaus T, Graf C, Stier S, Knapp M, Grunewald E, Ko YD, Sorger M. Variation in the Calpain-10 gene is not associated with gestational diabetes mellitus. Scandinavian Journal of Clinical and Laboratory Investigation 2013; 74:59-66. [DOI: 10.3109/00365513.2013.857427] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
7
|
Danquah I, Othmer T, Frank LK, Bedu-Addo G, Schulze MB, Mockenhaupt FP. The TCF7L2 rs7903146 (T) allele is associated with type 2 diabetes in urban Ghana: a hospital-based case-control study. BMC MEDICAL GENETICS 2013; 14:96. [PMID: 24059590 PMCID: PMC3848778 DOI: 10.1186/1471-2350-14-96] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 05/06/2013] [Accepted: 09/10/2013] [Indexed: 02/07/2023]
Abstract
Background Type 2 diabetes mellitus is increasing dramatically in sub-Saharan Africa, and genetic predisposition is likely involved in that. Yet, genetic variants known to confer increased susceptibility among Caucasians are far from being established in African populations. In Ghanaian adults, we examined associations of several of these polymorphisms with type 2 diabetes. Methods A hospital-based case–control study on type 2 diabetes (and hypertension) was conducted in Kumasi, Ghana. TCF7L2 rs7903146, KCNJ11 rs5219, PPARγ rs1801282 and CAPN10 rs3842570, rs3792267, and rs5030952 were typed and associations with type 2 diabetes and phenotypic traits examined. Results 675 patients with type 2 diabetes and 377 controls were compared. The minor allele frequency of the TCF7L2 (T) allele was 0.33. In the multivariate model, this allele increased the risk of type 2 diabetes by 39% (95% confidence interval (CI), 1.07-1.81; p = 0.014). The minor alleles KCNJ11 (G) and PPARγ (G) were practically absent (each, 0.001). Minor allele frequencies of CAPN10 were for -43 (A) 0.11 and for -63 (C) 0.46. These variants showed no significant associations with type 2 diabetes. Two CAPN10 haplotypes tended to protect against type 2 diabetes: 211 (aOR, 0.32; 95% CI, 0.03-1.92; p = 0.31) and 221 (aOR, 0.73; 95% CI, 0.48-1.10; p = 0.13). Conclusions In urban Ghana, the frequency of the TCF7L2 rs7903146 (T) allele is comparable to the one in Caucasians; the association with type 2 diabetes is slightly weaker. The risk allele KCNJ11 (G) and the protective allele PPARγ (G) are virtually absent. The potential influence of comparatively rare CAPN10 haplotypes on type 2 diabetes risk in this population requires further evaluation. Large-scale genetic studies among native Africans aiming at fine-mapping the candidate genes are needed to identify the actual factors involved in their increased susceptibility to type 2 diabetes.
Collapse
Affiliation(s)
- Ina Danquah
- Institute of Tropical Medicine and International Health, Charité, Universitätsmedizin Berlin, Spandauer Damm 130, 14050 Berlin, Germany.
| | | | | | | | | | | |
Collapse
|
8
|
Xu M, Bi Y, Cui B, Hong J, Wang W, Ning G. The new perspectives on genetic studies of type 2 diabetes and thyroid diseases. Curr Genomics 2013; 14:33-48. [PMID: 23997649 PMCID: PMC3580778 DOI: 10.2174/138920213804999138] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2012] [Revised: 11/16/2012] [Accepted: 11/19/2012] [Indexed: 12/18/2022] Open
Abstract
Recently, genome-wide association studies (GWAS) have led to the discovery of hundreds of susceptibility loci that are associated with complex metabolic diseases, such as type 2 diabetes and hyperthyroidism. The majority of the susceptibility loci are common across different races or populations; while some of them show ethnicity-specific distribution. Though the abundant novel susceptibility loci identified by GWAS have provided insight into biology through the discovery of new genes or pathways that were previously not known, most of them are in introns and the associated variants cumulatively explain only a small fraction of total heritability. Here we reviewed the genetic studies on the metabolic disorders, mainly type 2 diabetes and hyperthyroidism, including candidate genes-based findings and more recently the GWAS discovery; we also included the clinical relevance of these novel loci and the gene-environmental interactions. Finally, we discussed the future direction about the genetic study on the exploring of the pathogenesis of the metabolic diseases.
Collapse
Affiliation(s)
- Min Xu
- Key Laboratory for Endocrine and Metabolic Diseases of Ministry of Health, Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine, E-Institute of Shanghai Universities, Shanghai, China
| | | | | | | | | | | |
Collapse
|
9
|
Phillips CM. Nutrigenetics and metabolic disease: current status and implications for personalised nutrition. Nutrients 2013; 5:32-57. [PMID: 23306188 PMCID: PMC3571637 DOI: 10.3390/nu5010032] [Citation(s) in RCA: 91] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2012] [Revised: 12/12/2012] [Accepted: 12/21/2012] [Indexed: 12/11/2022] Open
Abstract
Obesity, particularly central adiposity, is the primary causal factor in the development of insulin resistance, the hallmark of the metabolic syndrome (MetS), a common condition characterized by dyslipidaemia and hypertension, which is associated with increased risk of cardiovascular disease (CVD) and type 2 diabetes (T2DM). Interactions between genetic and environmental factors such as diet and lifestyle, particularly over-nutrition and sedentary behavior, promote the progression and pathogenesis of these polygenic diet-related diseases. Their current prevalence is increasing dramatically to epidemic proportions. Nutrition is probably the most important environmental factor that modulates expression of genes involved in metabolic pathways and the variety of phenotypes associated with obesity, the MetS and T2DM. Furthermore, the health effects of nutrients may be modulated by genetic variants. Nutrigenomics and nutrigenetics require an understanding of nutrition, genetics, biochemistry and a range of “omic” technologies to investigate the complex interaction between genetic and environmental factors relevant to metabolic health and disease. These rapidly developing fields of nutritional science hold much promise in improving nutrition for optimal personal and public health. This review presents the current state of the art in nutrigenetic research illustrating the significance of gene-nutrient interactions in the context of metabolic disease.
Collapse
Affiliation(s)
- Catherine M Phillips
- HRB Centre for Diet and Health Research, Department of Epidemiology and Public Health, University College Cork, College Road, Cork, Ireland.
| |
Collapse
|
10
|
Perez-Martinez P, Garcia-Rios A, Delgado-Lista J, Perez-Jimenez F, Lopez-Miranda J. Metabolic syndrome: Evidences for a personalized nutrition. Mol Nutr Food Res 2011; 56:67-76. [DOI: 10.1002/mnfr.201100531] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2011] [Revised: 09/06/2011] [Accepted: 09/23/2011] [Indexed: 11/10/2022]
|
11
|
Martínez-Gómez LE, Cruz M, Martínez-Nava GA, Madrid-Marina V, Parra E, García-Mena J, Espinoza-Rojo M, Estrada-Velasco BI, Piza-Roman LF, Aguilera P, Burguete-García AI. A replication study of the IRS1, CAPN10, TCF7L2, and PPARG gene polymorphisms associated with type 2 diabetes in two different populations of Mexico. Ann Hum Genet 2011; 75:612-20. [PMID: 21834909 DOI: 10.1111/j.1469-1809.2011.00668.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Type 2 diabetes (T2D) is a chronic degenerative disease that involves the participation of several genetic and environmental factors. The objective of the study was to determine the association of the IRS1 (rs1801278), CAPN10 (rs3792267), TCF7L2 (rs7903146 and rs12255372), and PPARG (rs1801282) gene polymorphisms with T2D, in two different Mexican populations. We conducted a case-control replication study in the state of Guerrero and in Mexico City, with 400 subjects from Guerrero and 1065 from Mexico City. Data were analyzed by logistic regression, adjusting by ancestry, age, gender, and BMI, to determine the association with T2D. Heterozygosity for the Gly972Arg variant of the IRS1 gene showed the strongest association for T2D in both analyzed samples (OR = 2.43, 95% CI 1.12-5.26 and 2.64, 95% CI 1.37-5.10, respectively). In addition, an association of two SNPs of the TCF7L2 gene with T2D was observed in both cities: rs7903146, (for Guerrero OR = 1.98 CI95% 1.02-3.89 and for Mexico OR = 1.94 CI95% 1.31-2.88) and rs12255372 (OR = 1.79 CI95% 1.08-2.97, OR = 1.78 CI95% 1.17-2.71 respectively). We suggest that our results provide strong evidence that variation in the IRS1 and TCF7L2 genes confers susceptibility to T2D in our studied populations.
Collapse
Affiliation(s)
- Laura E Martínez-Gómez
- Centro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, México
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Perez-Martinez P, Delgado-Lista J, Garcia-Rios A, Ferguson JF, Gulseth HL, Williams CM, Karlström B, Kieć-Wilk B, Blaak EE, Helal O, Małczewska-Malec M, Defoort C, Risérus U, Saris WH, Lovegrove JA, Drevon CA, Roche HM, Lopez-Miranda J. Calpain-10 interacts with plasma saturated fatty acid concentrations to influence insulin resistance in individuals with the metabolic syndrome. Am J Clin Nutr 2011; 93:1136-41. [PMID: 21389182 DOI: 10.3945/ajcn.110.010512] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Calpain-10 protein (intracellular Ca(2+)-dependent cysteine protease) may play a role in glucose metabolism, pancreatic β cell function, and regulation of thermogenesis. Several CAPN10 polymorphic sites have been studied for their potential use as risk markers for type 2 diabetes and the metabolic syndrome (MetS). Fatty acids are key metabolic regulators that may interact with genetic factors and influence glucose metabolism. OBJECTIVE The objective was to examine whether the genetic variability at the CAPN10 gene locus is associated with the degree of insulin resistance and plasma fatty acid concentrations in subjects with MetS. DESIGN The insulin sensitivity index, glucose effectiveness, insulin resistance [homeostasis model assessment of insulin resistance (HOMA-IR)], insulin secretion (disposition index, acute insulin response, and HOMA of β cell function), plasma fatty acid composition, and 5 CAPN10 single nucleotide polymorphisms (SNPs) were determined in a cross-sectional analysis of 452 subjects with MetS participating in the LIPGENE dietary intervention cohort. RESULTS The rs2953171 SNP interacted with plasma total saturated fatty acid (SFA) concentrations, which were significantly associated with insulin sensitivity (P < 0.031 for fasting insulin, P < 0.028 for HOMA-IR, and P < 0.012 for glucose effectiveness). The G/G genotype was associated with lower fasting insulin concentrations, lower HOMA-IR, and higher glucose effectiveness in subjects with low SFA concentrations (below the median) than in subjects with the minor A allele (G/A and A/A). In contrast, subjects with the G/G allele with the highest SFA concentrations (above the median) had higher fasting insulin and HOMA-IR values and lower glucose effectiveness than did subjects with the A allele. CONCLUSION The rs2953171 polymorphism at the CAPN10 gene locus may influence insulin sensitivity by interacting with the plasma fatty acid composition in subjects with MetS. This trial was registered at clinicaltrials.gov as NCT00429195.
Collapse
Affiliation(s)
- Pablo Perez-Martinez
- Lipid and Atherosclerosis Unit, IMIBIC/Reina Sofia University Hospital/University of Cordoba, and CIBER Fisiopatologia Obesidad y Nutricion, Instituto de Salud Carlos III, Córdoba, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Ezzidi I, Mtiraoui N, Nemr R, Kacem M, Al-Khateeb GM, Mahjoub T, Almawi WY. Variants within the calpain-10 gene and relationships with type 2 diabetes (T2DM) and T2DM-related traits among Tunisian Arabs. DIABETES & METABOLISM 2010; 36:357-62. [PMID: 20570542 DOI: 10.1016/j.diabet.2010.03.005] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/20/2009] [Revised: 03/12/2010] [Accepted: 03/12/2010] [Indexed: 12/12/2022]
Abstract
BACKGROUND Common variations in the calpain 10 (CAPN10) gene variants UCSNP-43, UCSNP-19 and UCSNP-63, and the 112/121 diplotype, are associated with an increased risk of type 2 diabetes (T2DM) and T2DM-related traits. METHODS The association of UCSNP-43, -19 and -63 CAPN10 SNPs with T2DM was assessed in 917 Tunisian T2DM patients and 748 ethnically matched non-diabetic controls. CAPN10 genotyping was done by PCR-RFLP. RESULTS Significant differences in UCSNP-19 MAF, but not UCSNP-43 or -63, and genotype distribution were seen between patients and controls. Heterogeneity in UCSNP-19, but not UCSNP-43 and -63, genotype distribution was noted according to geographical origin. Obesity was associated with UCSNP-19, while raised fasting glucose was associated with UCSNP-63, and increased HDL was associated with UCSNP-43. Enrichment of homozygous UCSNP-19 2/2 was seen in overweight and obese compared with lean patients; logistic-regression analyses demonstrated a positive association of the 2/2 genotype with overweight [P=0.003; OR (95% CI)=2.07 (1.28-3.33)] and obese [P=0.021; OR (95% CI)=1.83 (1.10-3.07)] patients. Of the six CAPN10 haplotypes identified, significant enrichment of only haplotype 111 was seen in T2DM patients [Pc=0.034; OR (95% CI)=1.22 (1.06-1.41)], while the frequency of all identified CAPN10 diplotypes, including the high-risk 112/121, was comparable between patients and controls. CONCLUSION While CAPN10 UCSNP-19 SNP and haplotype 111 contribute to the risk of T2DM in Tunisian subjects, no significant association between CAPN10 diplotypes and T2DM was demonstrated.
Collapse
Affiliation(s)
- I Ezzidi
- Research Unit of Biology and Genetics of Hematological and Auto-immune diseases, Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia
| | | | | | | | | | | | | |
Collapse
|
14
|
Meyer TE, Boerwinkle E, Morrison AC, Volcik KA, Sanderson M, Coker AL, Pankow JS, Folsom AR. Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. Cancer Epidemiol Biomarkers Prev 2010; 19:558-65. [PMID: 20142250 DOI: 10.1158/1055-9965.epi-09-0902] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
There is a known inverse association between type 2 diabetes (T2D) and prostate cancer (PrCa) that is poorly understood. Genetic studies of the T2D-PrCa association may provide insight into the underlying mechanisms of this association. We evaluated associations in the Atherosclerosis Risk in Communities study between PrCa and nine T2D single nucleotide polymorphisms from genome-wide association studies of T2D (in CDKAL1, CDKN2A/B, FTO, HHEX, IGF2BP2, KCNJ11, PPARG, SLC30A8, and TCF7L2) and four T2D single nucleotide polymorphisms from pre-genome-wide association studies (in ADRB2, CAPN10, SLC2A2, and UCP2). From 1987 to 2000, there were 397 incident PrCa cases among 6,642 men ages 45 to 64 years at baseline. We used race-adjusted Cox proportional hazards models to estimate associations between PrCa and increasing number of T2D risk-raising alleles. PrCa was positively associated with the CAPN10 rs3792267 G allele [hazard ratio (HR) 1.20; 95% confidence interval (CI), 1.00-1.44] and inversely associated with the SLC2A2 rs5400 Thr110 allele (HR, 0.85; 95% CI, 0.72, 1.00), the UCP2 rs660339 Val55 allele (HR, 0.84; 95% CI, 0.73, 0.97) and the IGF2BP2 rs4402960 T allele (HR, 0.79; 95% CI, 0.61-1.02; blacks only). The TCF7L2 rs7903146 T allele was inversely associated with PrCa using a dominant genetic model (HR, 0.79; 95% CI, 0.65-0.97). Further knowledge of T2D gene-PrCa mechanisms may improve understanding of PrCa etiology.
Collapse
Affiliation(s)
- Tamra E Meyer
- Human Genetics Center and Division of Epidemiology, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Ezzidi I, Turki A, Messaoudi S, Chaieb M, Kacem M, Al-Khateeb GM, Mahjoub T, Almawi WY, Mtiraoui N. Common polymorphisms of calpain-10 and the risk of Type 2 Diabetes in a Tunisian Arab population: a case-control study. BMC MEDICAL GENETICS 2010; 11:75. [PMID: 20470430 PMCID: PMC2885359 DOI: 10.1186/1471-2350-11-75] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/04/2009] [Accepted: 05/15/2010] [Indexed: 12/16/2022]
Abstract
Background Genetic variations in the calpain-10 gene (CAPN10), in particular the at-risk diplotype (112/121), were previously implicated with increased risk of type 2 diabetes (T2D). Methods We examined the association of CAPN10 UCSNP-43 (rs3792267), UCSNP-19 (rs3842570), and UCSNP-63 (rs5030952) SNPs with T2D in 917 Tunisian T2D patients and 748 non-diabetic controls. CAPN10 genotyping was done by PCR-RFLP. Results Enrichment of UCSNP-19 2R (minor) allele and 2R/2R genotype was found in T2D patients; the allele and genotype distribution of UCSNP-43 and UCSNP-63 alleles and genotypes were not significantly different between patient groups and non-diabetic control subjects. Regression analysis demonstrated progressive increases in T2D risk in 3R/2R [OR (95% CI) = 1.35 (1.08 - 1.68)] and 2R/2R [OR (95% CI) = 1.61 (1.20 - 2.18)] genotypes. Of the six haplotypes detected, enrichment of haplotype 111 (UCSNP-43/UCSNP-19/UCSNP-63) was seen in patients (Pc = 0.034); the distribution of the other haplotypes was comparable between patients and control subjects; neither haplotype 211 nor haplotype 212 was observed. Furthermore, the frequency of all CAPN10 diplotypes identified, including the "high-risk diplotype (112/121) reported for Mexican-Americans and Northern Europeans, were comparable between patients and controls. Conclusions CAPN10 UCSNP-19 variant, and the 111 haplotype contribute to the risk of T2D in Tunisian subjects; no significant associations between CAPN10 diplotypes and T2D were demonstrated for Tunisians.
Collapse
Affiliation(s)
- Intissar Ezzidi
- Research Unit of Biology and Genetics of Hematological and Auto-immune diseases, Faculty of Pharmacy of Monastir, University of Monastir, Tunisia
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Zhou X, Wang Y, Zhang Y, Gao P, Zhu D. Association of CAPN10 gene with insulin sensitivity, glucose tolerance and renal function in essential hypertensive patients. Clin Chim Acta 2010; 411:1126-31. [PMID: 20406624 DOI: 10.1016/j.cca.2010.04.012] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2009] [Revised: 04/13/2010] [Accepted: 04/14/2010] [Indexed: 12/31/2022]
Abstract
BACKGROUND Essential hypertension (EH) is a common disorder, which can increase the risk for type 2 diabetes (T2D). Calpain-10 (CAPN10) gene was the first candidate gene of T2D identified through genome-wide linkage and positional cloning, but few works have focused on the relationship of CAPN10 with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) in EH patients. METHODS To identify the effect of UCSNP-43 and UCSNP-44 in CAPN10 gene on susceptibility to IFG/IGT, we conducted a case-control study in 961 EH patients with and without IFG/IGT among Han Chinese population. We also evaluated the impact of two SNPs on insulin sensitivity and glucose tolerance estimated through oral glucose tolerance test and renal functions by blood chemical assays. RESULTS The major findings of this study were that UCSNP-43 displayed higher G120 and AUCg. In addition, UCSNP-44 was found associated with IFG/IGT in EH patients, and associated with increased G30, G60, AUCg, Cederholm index, Scr and eGFR. The haplotype UCSNP-43-44 was detected associated with IFG/IGT susceptibility, G60, G120, I0, AUCg, Scr and eGFR by the linear regression with the adjustment for sex, age, BMI, mean blood pressures and ACEI/ARB treatment. CONCLUSIONS These findings provided some evidence that CAPN10 gene may play an important role in the pathogenesis of IFG/IGT in EH patients.
Collapse
Affiliation(s)
- Xiaoou Zhou
- State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | | | | | | | | |
Collapse
|
17
|
Haplotype association of calpain 10 gene variants with type 2 diabetes mellitus in an Irish sample. Ir J Med Sci 2010; 179:269-72. [DOI: 10.1007/s11845-010-0462-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2009] [Accepted: 01/03/2010] [Indexed: 01/16/2023]
|
18
|
MR I, HW W, RP P, RM S, CP GR. Genetic risk factors for type 2 diabetes with pharmacologic intervention in African-American patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009; 114:50-6. [PMID: 19643578 PMCID: PMC2753171 DOI: 10.1016/j.schres.2009.07.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/12/2009] [Revised: 06/30/2009] [Accepted: 07/06/2009] [Indexed: 10/20/2022]
Abstract
An increased prevalence of type 2 diabetes (T2D) in schizophrenia (SCZ) patients has been observed. Exposure to antipsychotics (APs) has been shown to induce metabolic dysregulation in some patients but not all treated patients. We hypothesized that important candidate genes for T2D may increase risk for T2D in African-American patients with SCZ or schizoaffective disorder. The PAARTNERS study comprises African-American families with at least one proband with SCZ or schizoaffective disorder. The current study of PAARTNERS SCZ and schizoaffective disorder cases (N=820) examined single nucleotide polymorphisms (SNPs) within select T2D candidate genes including transcription factor 7-like 2 (TCF7L2), calpain 10 (CAPN10), and ectoenzyme nucleotide pyrophosphatase phosphodiesterase 1 (ENNP1) for association with prevalent T2D. We report the association of TCF7L2 (rs7903146) with T2D under both additive and recessive models for the risk allele T. Specifically, the odds ratio (OR) for having T2D was 1.4 (p=0.03) under an additive model and 2.4 (p=0.004) under a recessive model. We also report a marginally significant TCF7L2 by AP treatment interaction that should be investigated in future studies. CAPN10 (rs3792267) was marginally associated with T2D with OR=1.5 (p=0.08) when considering the model GG vs. AG/AA with risk allele G. ENPP1 (rs1044498) was not associated with T2D. We conclude TCF7L2, a risk factor for T2D in the general population, is also a risk factor for T2D in African-American patients with SCZ or schizoaffective disorder. Research is needed to determine if T2D associated polymorphisms are of interest in the pharmacogenetics and future treatment choices of antipsychotics in African-American patients.
Collapse
Affiliation(s)
- Irvin MR
- Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham AL
| | - Wiener HW
- Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham AL
| | - Perry RP
- Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham AL
| | - Savage RM
- Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham AL
| | - Go R CP
- Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham AL
| |
Collapse
|
19
|
Yilmaz M, Yurtçu E, Demirci H, Ergün MA, Ersoy R, Karakoç A, Yetkin I, Cakir N, Ayvaz G, Arslan M. Calpain 10 gene single-nucleotide 44 polymorphism may have an influence on clinical and metabolic features in patients with polycystic ovary syndrome. J Endocrinol Invest 2009; 32:13-7. [PMID: 19337008 DOI: 10.1007/bf03345671] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
AIM This study was designed in order to examine the relationship between Calpain 10 [single-nucleotide polymorphism (SNP) 19,43,44,63] gene polymorphisms and clinical and hormonal characteristics in women with polycystic ovary syndrome (PCOS). MATERIALS AND METHODS One hundred and seven patients with PCOS and 114 healthy subjects were included in this study. Serum levels of sex steroids were measured for each individual. Insulin resistance (IR) was evaluated by the homeostasis model assessment (HOMA) and quantitative insulin-sensitivity check index (QUICKI) methods. Insulin and glucose responses to the oral glucose tolerance test (OGTT) were analyzed by calculating the areas under the curve for insulin (AUCI) and glucose by the trapezoidal methods.We used PCR and restriction fragment length polymorphism technique to examine Calpain 10 SNP 19, 43, 44, and 63 polymorphisms. RESULTS Allele distribution of Calpain 10 SNP 44 gene polymorphism was observed as significantly different between the groups. Calpain 10 SNP 44 TC genotype was found to be increased in PCOS subjects (69.15%) compared to the control subjects (50%). However, when compared to control subjects, patients with PCOS had similar Calpain 10 SNP 19, Calpain 10 SNP 43, and SNP 63 gene polymorphisms. When compared with normal Calpain 10 gene SNP 44 allele in PCOS subjects, subjects with PCOS having Calpain 10 gene SNP 44 allele polymorphism had higher free testosterone, androstenedione, DHEA-S, and fasting insulin levels. Also, PCOS women with Calpain 10 gene SNP 44 allele polymorphism had high Ferriman-Gallwey (F-G) score, acne, prevalence of menstrual disturbances, waist-hip ratio, HOMA-IR, AUCI levels and low QUICKI levels. CONCLUSION The findings show that Calpain 10 gene SNP 44 allele polymorphism may have a role in PCOS pathogenesis. However, larger-scale studies are needed in this field.
Collapse
Affiliation(s)
- M Yilmaz
- Department of Endocrinology and Metabolism, Faculty of Medicine, Kirikkale University, Kirikkale, Turkey.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet 2008; 9:403-33. [PMID: 18593304 DOI: 10.1146/annurev.genom.9.081307.164258] [Citation(s) in RCA: 508] [Impact Index Per Article: 31.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Comparative studies of ethnically diverse human populations, particularly in Africa, are important for reconstructing human evolutionary history and for understanding the genetic basis of phenotypic adaptation and complex disease. African populations are characterized by greater levels of genetic diversity, extensive population substructure, and less linkage disequilibrium (LD) among loci compared to non-African populations. Africans also possess a number of genetic adaptations that have evolved in response to diverse climates and diets, as well as exposure to infectious disease. This review summarizes patterns and the evolutionary origins of genetic diversity present in African populations, as well as their implications for the mapping of complex traits, including disease susceptibility.
Collapse
Affiliation(s)
- Michael C Campbell
- Department of Genetics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19107, USA.
| | | |
Collapse
|
21
|
Sáez ME, González-Sánchez JL, Ramírez-Lorca R, Martínez-Larrad MT, Zabena C, González A, Morón FJ, Ruiz A, Serrano-Ríos M. The CAPN10 gene is associated with insulin resistance phenotypes in the Spanish population. PLoS One 2008; 3:e2953. [PMID: 18698425 PMCID: PMC2495037 DOI: 10.1371/journal.pone.0002953] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2008] [Accepted: 07/24/2008] [Indexed: 01/09/2023] Open
Abstract
Cardiovascular disease is the leading cause of morbidity and mortality in the industrialized world. Familial aggregation of cardiovascular risk factors is a frequent finding, but genetic factors affecting its presentation are still poorly understood. The calpain 10 gene (CAPN10) has been associated with type 2 diabetes (T2DM), a complex metabolic disorder with increased risk of cardiovascular disease. Moreover, the CAPN10 gene has been associated with the presence of metabolic syndrome (MS) in T2DM and in polycystic ovary syndrome (PCOS). In this work, we have analysed whether the polymorphisms UCSNP44, -43, -19 and -63 are related to several cardiovascular risk factors in the context of MS. Molecular analysis of CAPN10 gene was performed in 899 individuals randomly chosen from a cross-sectional population-based epidemiological survey. We have found that CAPN10 gene in our population is mainly associated with two indicators of the presence of insulin resistance: glucose levels two hours after a 75-g oral glucose tolerance test (OGTT) and HOMA values, although cholesterol levels and blood pressure values are also influenced by CAPN10 variants. In addition, the 1221/1121 haplogenotype is under-represented in individuals that fulfil the International Diabetes Federation (IDF) diagnostic criteria for MS. Our results suggest that CAPN10 gene is associated with insulin resistance phenotypes in the Spanish population.
Collapse
Affiliation(s)
- María E Sáez
- Neocodex, Departamento de Genómica Estructural, Seville, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
Definition of the phenotype is crucial in designing any genetic study, especially an association study, intended to detect the disease predisposing genes. In this chapter, we review the different types of phenotypes such as discrete or continuous and discuss the issues impacting on the phenotype definition related to study design, specifically, the impact of diagnostic error (misclassification) in case-control studies and measurement error in continuous traits. We show that the power of a study depends heavily on the phenotype measured and that misclassification or measurement error can dramatically reduce the power. We also suggest some possible responses to these challenges.
Collapse
Affiliation(s)
- Mary K Wojczynski
- Department of Biostatistics, Section on Statistical Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | | |
Collapse
|
23
|
Variations in the calpain-10 gene are associated with the risk of type 2 diabetes and hypertension in northern Han Chinese population. Chin Med J (Engl) 2007. [DOI: 10.1097/00029330-200712020-00012] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
|
24
|
Frances CP, Conde MC, Saez ME, Diez SF, Rey CM, Ramírez-Armengol JA, Pascual MH, Gonzalez-Perez A, Torres PP, Real LM, Serrano-Rios M, López JLG, Ruiz A, Royo JL. Identification of a protective haplogenotype within CAPN10 gene influencing colorectal cancer susceptibility. J Gastroenterol Hepatol 2007; 22:2298-302. [PMID: 17559371 DOI: 10.1111/j.1440-1746.2007.04843.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND AND AIM Colorectal cancer (CRC) is one of the most prevalent types of cancer affecting both men and women in developed countries. Clinical and molecular evidence suggests that there are multiple biochemical pathways involved in its susceptibility, pathogenesis and prognosis. Several studies have reported a significant association between the incidence of CRC and type 2 diabetes mellitus (T2DM). However, genes associated with both conditions are rare. METHOD We have analyzed the CAPN10 gene, a T2DM locus, using UCSNP-43, -44, -19, and -63 markers, looking for differences between 371 CRC patients and 605 unrelated controls of Spanish origin. RESULTS We found that UCSNP-44 allele C is swept out from cases (OR = 0.16, P = 0.005). Moreover, the frequency of 2111/2111 haplogenotype is also statistically lower than expected in CRC patients (P = 0.006). CONCLUSION Taken together, our results indicate a recessive model for the effect of CAPN10 variant UCSNP-44 influencing the risk of CRC and suggest a novel genetic link between T2DM and colon carcinoma.
Collapse
Affiliation(s)
- Carmen P Frances
- Endoscopy Central Service, San Carlos Clinical Hospital, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Sale MM, Smith SG, Mychaleckyj JC, Keene KL, Langefeld CD, Leak TS, Hicks PJ, Bowden DW, Rich SS, Freedman BI. Variants of the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in an African-American population enriched for nephropathy. Diabetes 2007; 56:2638-42. [PMID: 17601994 DOI: 10.2337/db07-0012] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVE Recently, variants in the TCF7L2 gene have been reported to be associated with type 2 diabetes across multiple Europid populations, but only one small sample of African-American type 2 diabetic patients has been examined. Our objective was to investigate the importance of TCF7L2 in a larger African-American case-control population. RESEARCH DESIGN AND METHODS We investigated single nucleotide polymorphisms (SNPs) in six known type 2 diabetes genes in 577 African-American case subjects with type 2 diabetes enriched for nephropathy and 596 African-American control subjects. Additionally, we genotyped 70 ancestry-informative markers (AIMs) to apply adjustments for differences in ancestral proportions. RESULTS The most significant associations were observed with TCF7L2 intron 3 SNPs rs7903146 (additive P = 4.10 x 10(-6), odds ratio [OR] 1.51; admixture-adjusted P(a) = 3.77 x 10(-6)) and rs7901695 (P = 0.001, OR 1.30; P(a) = 0.003). The 2-SNP haplotype containing these SNPs was also associated with type 2 diabetes (P = 3 x 10(-5)). Modest associations were also seen with TCF7L2 intron 4 SNPs rs7895340, rs11196205, and rs12255372 (0.01 < P < 0.05; 0.03 < P(a) < 0.08), as well as with ATP-sensitive inwardly rectifying potassium channel subunit Kir6.2 (KCNJ11) and hepatocyte nuclear factor 4-alpha (HNF4A) SNPs (0.01 < P < 0.05; 0.01 < P(a) < 0.41). No significant associations were detected with genotyped calpain 10 (CAPN10), peroxisome proliferator-activated receptor gamma (PPARG), and transcription factor 1 (TCF1) SNPs. CONCLUSIONS This study indicates that variants in the TCF7L2 gene significantly contribute to diabetes susceptibility in African-American populations.
Collapse
Affiliation(s)
- Michèle M Sale
- Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Elbein SC. Evaluation of polymorphisms known to contribute to risk for diabetes in African and African-American populations. Curr Opin Clin Nutr Metab Care 2007; 10:415-9. [PMID: 17563458 DOI: 10.1097/mco.0b013e3281e2c99a] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
PURPOSE OF REVIEW Populations of direct African ancestry have much greater genetic diversity than do other populations. African-American populations exhibit twice the prevalence of type 2 diabetes as compared with their Caucasian counterparts. African-American populations are likely to have unique genetic susceptibility to type 2 diabetes. This review addresses current knowledge of susceptibility genes that are shared with other groups and those that are unique to populations of African descent. RECENT FINDINGS When compared with the plethora of Caucasian studies, relatively few studies have been conducted in African or African-American populations. The most exciting findings have been family-based linkage studies, which point to multiple regions that may harbor susceptibility genes. Recent work suggests that the major Caucasian locus, TCF7L2, plays a role in some African-based populations, whereas unique factors remain to be confirmed. SUMMARY Although progress has been made in finding the genetic cause of type 2 diabetes in African and African-American populations, at this time no variant can be considered unequivocally confirmed as a diabetes susceptibility locus.
Collapse
Affiliation(s)
- Steven C Elbein
- Medicine and Research Services, Central Arkansas Veterans Affairs Healthcare System, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
| |
Collapse
|
27
|
Harris F, Biswas S, Singh J, Dennison S, Phoenix DA. Calpains and their multiple roles in diabetes mellitus. Ann N Y Acad Sci 2007; 1084:452-80. [PMID: 17151322 DOI: 10.1196/annals.1372.011] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Type 2 diabetes mellitus (T2DM) can lead to death without treatment and it has been predicted that the condition will affect 215 million people worldwide by 2010. T2DM is a multifactorial disorder whose precise genetic causes and biochemical defects have not been fully elucidated, but at both levels, calpains appear to play a role. Positional cloning studies mapped T2DM susceptibility to CAPN10, the gene encoding the intracellular cysteine protease, calpain 10. Further studies have shown a number of noncoding polymorphisms in CAPN10 to be functionally associated with T2DM while the identification of coding polymorphisms, suggested that mutant calpain 10 proteins may also contribute to the disease. Here we review recent studies, which in addition to the latter enzyme, have linked calpain 5, calpain 3, and its splice variants, calpain 2 and calpain 1 to T2DM-related metabolic pathways along with T2DM-associated phenotypes, such as obesity and impaired insulin secretion, and T2DM-related complications, such as epithelial dysfunction and diabetic cataract.
Collapse
Affiliation(s)
- Frederick Harris
- Department of Forensic and Investigative Science, University of Central Lancashire, Preston, PR1 2HE, United Kingdom
| | | | | | | | | |
Collapse
|
28
|
Abstract
The etiology of type 2 diabetes (T2D) is complex and remains poorly understood. Differences in individual susceptibility to this condition reflect the action of multiple variants, each of which confers a modest effect, and their interactions with a variety of environmental exposures. Several complementary approaches to the identification of the etiological variants have been adopted, though, for all, association analyses provide the final common pathway. The genes and/or chromosomal regions studied have been selected on the basis of their presumed biological relevance to diabetes, known involvement in monogenic forms, or animal models of the condition and/or signals arising from whole-genome linkage scans. These association studies have featured a wide variety of designs and analytical approaches, but reliable biological insights have been few, largely because of difficulties in obtaining reproducible findings. However, in recent years, several examples of robustly replicated associations have emerged, largely as a result of an emphasis on the need for improved power and more appropriate analysis and interpretation. New strategies for the large-scale identification of T2D susceptibility variants are now becoming possible, including the prospect of genuine genome-wide association scans, but caution in their design, analysis, and interpretation remains essential.
Collapse
Affiliation(s)
- Eleftheria Zeggini
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, UK
| | | |
Collapse
|
29
|
Jensen DP, Urhammer SA, Eiberg H, Borch-Johnsen K, Jørgensen T, Hansen T, Pedersen O. Variation in CAPN10 in relation to type 2 diabetes, obesity and quantitative metabolic traits: studies in 6018 whites. Mol Genet Metab 2006; 89:360-7. [PMID: 16857402 DOI: 10.1016/j.ymgme.2006.06.003] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2006] [Accepted: 06/06/2006] [Indexed: 11/18/2022]
Abstract
The first type 2 diabetes (T2D) gene to be identified in a genome wide scan followed by positional cloning was CAPN10 encoding the cysteine protease calpain-10. Subsequently, a large number of studies have investigated variation in CAPN10 in relation to T2D. Two CAPN10 single nucleotide polymorphisms (SNPs), the SNP43 (rs3792267) and the SNP44 (rs2975760), have been associated with T2D in some, but not all studies conducted in a wide range of ethnicities. We investigated the two SNPs for association with T2D in a relatively large, homogenous population of Danish whites (n = 1359 T2D cases, n = 4659 normoglycemic and glucose-tolerant control subjects), however, no significant associations of the SNP43 or the SNP44 variant with T2D were found. Neither were the two variants associated with obesity, and no association of either variant with diabetes-related quantitative traits was found in a study involving a population-based sample of 5698 middle-aged subjects. Meta-analyses, however, of the present and previously published studies involving 15,368 (SNP43) or 13,628 (SNP44) subjects yielded odds ratios of 1.09 (95% CI 1.02-1.16, p = 0.007) and 1.15 (1.07-1.23, p = 0.0002), respectively, for association with T2D. In conclusion, in a relatively large study sample of whites we found no consistent evidence of association of the CAPN10 SNP43 or SNP44 with T2D, obesity, or related quantitative traits, although meta-analyses of these two CAPN10 SNPs demonstrated an association with T2D.
Collapse
Affiliation(s)
- Dorit P Jensen
- Steno Diabetes Center, Niels Steensens Vej 2, DK-2820 Gentofte, Copenhagen, Denmark.
| | | | | | | | | | | | | |
Collapse
|
30
|
Affiliation(s)
- Yukio Horikawa
- Department of Diabetes and Endocrinology, Gifu University School of Medicine, Yanagido, Gifu, Japan
| |
Collapse
|
31
|
Berger M, Stassen HH, Köhler K, Krane V, Mönks D, Wanner C, Hoffmann K, Hoffmann MM, Zimmer M, Bickeböller H, Lindner TH. Hidden population substructures in an apparently homogeneous population bias association studies. Eur J Hum Genet 2006; 14:236-44. [PMID: 16333311 DOI: 10.1038/sj.ejhg.5201546] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Linkage- and association-based approaches have been applied to attempt to unravel the genetic predisposition for complex diseases. However, studies often report contradictory results even when similar population backgrounds are investigated. Unrecognized population substructures could possibly explain these inconsistencies. In an apparently homogeneous German sample of 612 patients with type 2 diabetic and end-stage diabetic nephropathy and 214 healthy controls, we tested for hidden population substructures and their possible effects on association. Using a genetic vector space analysis of genotypes of 20 microsatellite markers, we identified four distinct subsets of cases and controls. The significance of these substructures was demonstrated by subsequent association analyses, using three genetic markers (UCSNP-43,-19,-63; intron 3 of the calpain-10 gene). In the undivided sample, we found no association between individual SNPs or any haplogenotypes (ie the genotype combination of two multilocus haplotypes) and type 2 diabetes. In contrast, when analyzing the four groups separately, we found that there was evidence for association of the common C allele of UCSNP-63 with the trait in the largest group (n=547 cases/101 controls; P=0.002). In this subset haplotype 112 was more frequent in controls than in cases (P=0.006; haplogenotype 112/121: odds ratio (OR)=0.27, 95% confidence intervals (CI)=0.13-0.57), indicating a protective effect against the development of type 2 diabetes. Our study demonstrates that unconsidered population substructures (ethnicity-dependent factors) can severely bias association studies.
Collapse
Affiliation(s)
- Mario Berger
- Division of Nephrology, Department of Medicine, University of Würzburg, Würzburg, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Huang QY, Cheng MR, Ji SL. Linkage and Association Studies of the Susceptibility Genes for Type 2 Diabetes. ACTA ACUST UNITED AC 2006; 33:573-89. [PMID: 16875315 DOI: 10.1016/s0379-4172(06)60087-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Type 2 diabetes mellitus (T2DM) is a complex disease characterized by hyperglycemia, insulin resistance, and impaired insulin secretion. T2DM is under strong genetic control. Identification and characterization of genes involved in determining T2DM will contribute to a greater understanding of the pathogenesis of T2DM, and ultimately might lead to the development of better diagnosis, prevention and treatment strategies. Efforts to identify T2DM susceptibility genes have focused on candidate gene approach (association studies) and genome-wide scans (linkage analyses). In this article, we review the current status for mapping and identification of genes for T2DM, with a focus on some promising regions (or genes) and future prospects.
Collapse
Affiliation(s)
- Qing-Yang Huang
- College of Life Science, Central China Normal University, Wuhan 430079, China.
| | | | | |
Collapse
|
33
|
Pihlajamäki J, Salmenniemi U, Vänttinen M, Ruotsalainen E, Kuusisto J, Vauhkonen I, Kainulainen S, Ng MCY, Cox NJ, Bell GI, Laakso M. Common polymorphisms of calpain-10 are associated with abdominal obesity in subjects at high risk of type 2 diabetes. Diabetologia 2006; 49:1560-6. [PMID: 16752174 DOI: 10.1007/s00125-006-0270-z] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/23/2006] [Accepted: 03/09/2006] [Indexed: 12/31/2022]
Abstract
AIMS/HYPOTHESIS The mechanisms by which the calpain-10 gene (CAPN10) affects the risk of type 2 diabetes are unclear. Therefore, we investigated the effects of four polymorphisms in CAPN10 (single nucleotide polymorphism [SNP]-43, SNP-44, Insertion/Deletion [Indel]-19 and SNP-63) on insulin secretion, insulin action and abdominal fat distribution in offspring of patients with type 2 diabetes. SUBJECTS AND METHODS Insulin secretion was determined by an IVGTT, insulin action by the hyperinsulinaemic-euglycaemic clamp and abdominal fat distribution by computed tomography in 158 non-diabetic offspring (age 34.9+/-6.3 years [mean+/-SD], BMI 26.2+/-4.9 kg/m(2)) of type 2 diabetic patients. RESULTS SNP-43 (p=0.009 over the three genotypes, adjusted for age, sex, BMI and family relationship) and haplotypes carrying the A allele of SNP-43 were associated with intra-abdominal fat area. The A allele of SNP-43 was associated with intra-abdominal fat area in men (p=0.014) but not in women. SNP-44, InDel-19 and SNP-63 were not associated with intra-abdominal fat area or insulin action. Furthermore, we demonstrated in a separate sample of middle-aged men (n=234) who had a history of type 2 diabetes in first-degree relatives that the A allele of SNP-43 was associated with a large waist circumference, and high insulin levels in an OGTT. CONCLUSIONS/INTERPRETATION SNP-43 of CAPN10 may contribute to the risk of diabetes by regulating abdominal obesity in subjects with high risk of type 2 diabetes.
Collapse
Affiliation(s)
- J Pihlajamäki
- University of Kuopio, Department of Medicine, Kuopio, Finland.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Trajkovski M, Mziaut H, Schwarz PE, Solimena M. Genes of type 2 diabetes in beta cells. Endocrinol Metab Clin North Am 2006; 35:357-69, x. [PMID: 16632098 DOI: 10.1016/j.ecl.2006.02.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Type 2 diabetes is a complex polygenic metabolic disorder of epidemic proportions. This review provides a brief overview of the susceptibility genes in type 2 diabetes that primarily affect pancreatic 3 cells, with emphasis on their function and most relevant polymorphisms. We focus on calpain 10, the only susceptibility gene identified thus far through a positional cloning approach in subjects with diabetes.
Collapse
Affiliation(s)
- Mirko Trajkovski
- Experimental Diabetology, Carl Gustav Carus Medical School, Dresden University of Technology, Fetscherstrasse 74, 01307 Dresden, Germany
| | | | | | | |
Collapse
|
35
|
Einarsdottir E, Mayans S, Ruikka K, Escher SA, Lindgren P, Agren A, Eliasson M, Holmberg D. Linkage but not association of calpain-10 to type 2 diabetes replicated in northern Sweden. Diabetes 2006; 55:1879-83. [PMID: 16731857 DOI: 10.2337/db05-1495] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
We present data from a genome-wide scan identifying genetic factors conferring susceptibility to type 2 diabetes. The linkage analysis was based on 59 families from northern Sweden, consisting of a total of 129 cases of type 2 diabetes and 19 individuals with impaired glucose tolerance. Model-free linkage analysis revealed a maximum multipoint logarithm of odds score of 3.19 for D2S2987 at 267.7 cM (P=0.00058), suggesting that a gene conferring susceptibility to type 2 diabetes in the northern Swedish population resides in the 2q37 region. These data replicate, in a European population, previously identified linkage of marker loci in this region to type 2 diabetes in Mexican Americans. In contrast, no evidence in support of association to the previously identified single nucleotide polymorphisms in the calpain-10 gene was observed in a case-control cohort derived from the same population.
Collapse
Affiliation(s)
- Elisabet Einarsdottir
- Department of Medical Biosciences, Division of Medical and Clinical Genetics, Umeå University, SE-901 87 Umeå, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
36
|
González A, Sáez ME, Aragón MJ, Galán JJ, Vettori P, Molina L, Rubio C, Real LM, Ruiz A, Ramírez-Lorca R. Specific haplotypes of the CALPAIN-5 gene are associated with polycystic ovary syndrome. Hum Reprod 2006; 21:943-51. [PMID: 16396936 DOI: 10.1093/humrep/dei443] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. The aim of the present study was to investigate the role of CALPAIN-5 (CAPN5) gene in PCOS susceptibility. METHODS We analysed four intronic polymorphisms of the CAPN5 gene in 148 well-characterized women with PCOS and 606 unrelated controls. We performed a case-control study and an intracohort analysis of clinical characteristics associated with PCOS. RESULTS Analysis of haplotypes distribution between PCOS population compared to controls showed a strong deviation (P = 0.00029). The haplotypes GGCA and GGTG were overrepresented in PCOS patients (P = 0.009 and P = 0.001, respectively). In addition, we identified several CAPN5 haplotypes associated with phenotypic differences observed between PCOS patients, such as the presence of obesity (P = 0.02), cardiovascular complications (P = 0.02), familial antecedents of obesity (P = 0.003) and of hypertension (P = 0.007) and type 2 diabetes mellitus aggregation (P = 0.04). CONCLUSIONS These results suggest a role of CAPN5 gene in PCOS susceptibility in humans. Moreover, novel candidate risk alleles have been identified, within CAPN5 gene, which could be associated with important phenotypic and prognosis differences observed in PCOS patients.
Collapse
Affiliation(s)
- A González
- Centro Avanzado de Fertilidad (CAF), Unidad de Reproducción y Genética Humana, Instituto Médico Serman, Hospital Virgen de las Montañas, Cádiz, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
Calpain-10 (CAPN10) is the first diabetes gene to be identified through a genome scan. Many investigators, but not all, have subsequently found associations between CAPN10 polymorphism and type 2 diabetes (T2D) as well as insulin action, insulin secretion, aspects of adipocyte biology and microvascular function. However, this has not always been with the same single nucleotide polymorphism (SNP) or haplotype or the same phenotype, suggesting that there might be more than one disease-associated CAPN10 variant and that these might vary between ethnic groups and the phenotype under study. Our understanding of calpain-10 physiological action has also been greatly augmented by our knowledge of the calpain family domain structure and function, and the relationship between calpain-10 and other calpains is discussed here. Both genetic and functional data indicates that calpain-10 has an important role in insulin resistance and intermediate phenotypes, including those associated with the adipocyte. In this regard, emerging evidence would suggest that calpain-10 facilitates GLUT4 translocation and acts in reorganization of the cytoskeleton. Calpain-10 is also an important molecule in the beta-cell. It is likely to be a determinant of fuel sensing and insulin exocytosis, with actions at the mitochondria and plasma membrane respectively. We postulate that the multiple actions of calpain-10 may relate to its different protein isoforms. In conclusion, the discovery of calpain-10 by a genetic approach has identified it as a molecule of importance to insulin signaling and secretion that may have relevance to the future development of novel therapeutic targets for the treatment of T2D.
Collapse
Affiliation(s)
- Mark D Turner
- Centre for Diabetes and Metabolic Medicine, Institute of Cell and Molecular Science, Barts and The London Queen Mary's School of Medicine and Dentistry, University of London, London, E1 2AT United Kingdom.
| | | | | |
Collapse
|
38
|
Ridderstråle M, Parikh H, Groop L. Calpain 10 and type 2 diabetes: are we getting closer to an explanation? Curr Opin Clin Nutr Metab Care 2005; 8:361-6. [PMID: 15930958 DOI: 10.1097/01.mco.0000172573.25902.33] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE OF REVIEW A variation in the gene encoding the cysteine protease calpain 10 (CAPN10) was recently linked and associated with type 2 diabetes by positional cloning. This positional cloning was a follow-up investigation to the identification of a diabetes-linked region on human chromosome 2 identified by genome-wide scanning a few years earlier. In this paper we give a general background on the genetic studies performed on CAPN10 to date, and review the most recent studies on the functional role of calpain 10. RECENT FINDING A haplotype or haplotype combination comprising three intronic single nucleotide polymorphisms (UCSNP-43, 19, and 63) were associated with a threefold increased risk of type 2 diabetes in the population in which linkage was first found. Another polymorphism, UCSNP-44, which is in linkage disequilibrium with a coding single-nucleotide polymorphism (Thr504Ala), has subsequently been associated with type 2 diabetes in extensive meta-analyses. Meanwhile, initial studies probing the possible role of calpain-10, completely unknown at the time, are now being pursued, both in isolated cells and humans. SUMMARY The positional cloning of CAPN10 as a candidate gene for type 2 diabetes has been particularly fruitful. Not only has it identified an important and surprising piece of the puzzle underlying the development of diabetes, but it has also modelled and paved the way for investigations concerning complex genetic diseases other than type 2 diabetes.
Collapse
Affiliation(s)
- Martin Ridderstråle
- Department of Clinical Sciences, Lund University, Wallenberg Laboratory, University Hospital MAS, S-205 02 Malmö, Sweden.
| | | | | |
Collapse
|
39
|
Abstract
Type 2 diabetes (T2D) has become a health-care problem worldwide, with the rise in disease prevalence being all the more worrying as it not only affects the developed world but also developing nations with fewer resources to cope with yet another major disease burden. Furthermore, the problem is no longer restricted to the ageing population, as young adults and children are also being diagnosed with T2D. In recent years, there has been a surge in the number of genetic studies of T2D in attempts to identify some of the underlying risk factors. In this review, I highlight the main genes known to cause uncommon monogenic forms of diabetes (e.g. maturity-onset diabetes of the young--MODY--and insulin resistance syndromes), as well as describe some of the main approaches used to identify genes involved in the more common forms of T2D that result from the interaction between environmental risk factors and predisposing genotypes. Linkage and candidate gene studies have been highly successful in the identification of genes that cause the monogenic variants of diabetes and, although progress in the more common forms of T2D has been slow, a number of genes have now been reproducibly associated with T2D risk in multiple studies. These are discussed, as well as the main implications that the diabetes gene discoveries will have in diabetes treatment and prevention.
Collapse
Affiliation(s)
- I Barroso
- Metabolic Disease Group, The Wellcome Trust Sanger Institute, Cambridge, UK.
| |
Collapse
|
40
|
Abstract
Type 2 diabetes (T2DM) comprises a group of entities with different genetic causes. In most patients, T2DM results from alterations of various genes, each having a partial and additive effect. The inheritance pattern is thus complex, and environmental factors play an important role in favoring or delaying the expression of the disease. The identification of susceptibility genes and genetic variants requires different methodological approaches. Here we address some of the most important strategies and findings on the genomic basis of T2DM, as well as evidence of genetic heterogeneity among populations. The identification of the underlying genetic causes of T2DM and other related traits such as obesity and hypertension will lead to the development of new therapeutic targets likely to impact the way we treat these diseases. Survival and quality of life for T2DM patients is expected to eventually increase, significantly lessening the socioeconomic burden of the disease.
Collapse
Affiliation(s)
- María Teresa Tusié Luna
- Unidad de Biología Molecular y Medicina Genómica del Instituto de Investigaciones Biomédicas de la UNAM y Nutrición Salvador Zubirán, Mexico City, Mexico DF.
| |
Collapse
|
41
|
Logie LJ, Brown AE, Yeaman SJ, Walker M. Calpain inhibition and insulin action in cultured human muscle cells. Mol Genet Metab 2005; 85:54-60. [PMID: 15862281 DOI: 10.1016/j.ymgme.2005.01.003] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2004] [Revised: 01/04/2005] [Accepted: 01/04/2005] [Indexed: 11/26/2022]
Abstract
Variation in the calpain 10 gene has been reported to increase susceptibility to type 2 diabetes. Part of this susceptibility appears to be mediated by a decrease in whole body insulin sensitivity. As skeletal muscle is the primary tissue site of the peripheral insulin resistance in type 2 diabetes, the aim of this study was to use a human skeletal muscle cell culture system to explore the effects of calpain inhibition on insulin action. Calpain 10 mRNA and protein expression was examined in cultured myoblasts, myotubes, and whole skeletal muscle from non-diabetic subjects using RT-PCR and Western blotting. Changes in insulin-stimulated glucose uptake and glycogen synthesis in response to the calpain inhibitors ALLN and ALLM were measured. Calpain 10 expression was confirmed in cultured human myoblasts, myotubes, and native skeletal muscle. Insulin-stimulated glucose uptake was significantly decreased following preincubation with ALLN [404+/-40 vs 505+/-55 (mean+/-SEM)pmol/mg/min; with vs without ALLN: p = 0.04] and ALLM [455+/-38 vs 550+/-50 pmol/mg/min; with vs without ALLM: p = 0.025] in day 7 fused myotubes, but not in myoblasts. Neither ALLN nor ALLM affected insulin-stimulated glycogen synthesis in myoblasts or myotubes. These studies confirm calpain 10 expression in cultured human muscle cells and support a role for calpains in insulin-stimulated glucose uptake in human skeletal muscle cells that may be relevant to the pathogenesis of the peripheral insulin resistance in type 2 diabetes.
Collapse
Affiliation(s)
- L J Logie
- School of Clinical Medical Sciences, University of Newcastle upon Tyne, Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
| | | | | | | |
Collapse
|
42
|
Chen Y, Kittles R, Zhou J, Chen G, Adeyemo A, Panguluri RK, Chen W, Amoah A, Opoku V, Acheampong J, Agyenim-Boateng K, Eghan BA, Nyantaki A, Oli J, Okafor G, Ofoegbu E, Osotimehin B, Abbiyesuku F, Johnson T, Fasanmade O, Rufus T, Furbert-Harris P, Daniel HI, Berg KA, Collins FS, Dunston GM, Rotimi CN. Calpain-10 gene polymorphisms and type 2 diabetes in West Africans: the Africa America Diabetes Mellitus (AADM) Study. Ann Epidemiol 2005; 15:153-9. [PMID: 15652721 DOI: 10.1016/j.annepidem.2004.05.014] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2003] [Accepted: 05/25/2004] [Indexed: 01/06/2023]
Abstract
PURPOSE To investigate whether the three single nucleotide polymorphisms (SNPs), SNP-43, -56, and -63 of CAPN10 were associated with type 2 diabetes in a West African cohort. METHODS A total of 347 diabetic subjects and 148 unaffected controls from four ethnic groups in two West African countries were enrolled in this study. After genotyping three SNPs of CAPN10 and one SNP from CYP19, the allele, genotype, and haplotype frequencies as well as the odds ratios were calculated to test their association with type 2 diabetes. RESULTS None of the alleles or genotypes was associated with type 2 diabetes. Although statistical analysis indicated that haplotype 221 was associated with type 2 diabetes (OR, 3.765; 95% CI, 1.577-8.989) in the two ethnic groups of Nigeria, the same haplotype did not show any association with type 2 diabetes in the two ethnic groups in Ghana (OR, 0.906; 95% CI, 0.322-2.552). CONCLUSION Considering the relatively low frequency of haplotype 221 and that none of the haplotypes including 221 was associated with any of the diabetes-related quantitative traits tested, it is concluded that SNP-43, -56, and -63 of the CAPN10 gene variants may play a limited role in the risk of type 2 diabetes risks in this cohort of West Africans.
Collapse
Affiliation(s)
- Yuanxiu Chen
- College of Medicine, National Human Genome Center at Howard University, Washington, DC 20059, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Tripathy D, Eriksson KF, Orho-Melander M, Fredriksson J, Ahlqvist G, Groop L. Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in Type 2 diabetes. Diabetologia 2004; 47:782-93. [PMID: 15114470 DOI: 10.1007/s00125-004-1393-8] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2003] [Accepted: 01/19/2004] [Indexed: 11/24/2022]
Abstract
AIMS/HYPOTHESIS The aim of the study was to evaluate the relationship between insulin sensitivity, beta cell function and glucose tolerance, and its dependence on variants in the newly identified Type 2 diabetes susceptibility gene, calpain-10 ( CAPN10). METHODS We studied 203 men of the same age but with varying degrees of glucose tolerance. These men participated in (i) an oral glucose tolerance test, (ii) a euglycaemic clamp combined with indirect calorimetry and infusion of [3-(3)H]-glucose and (iii) a stepwise assessment of acute insulin response to arginine (AIR) at three different glucose concentrations (fasting, 14 and 28 mmol/l). RESULTS There was a linear increase in NEFA levels ( p<0.0005) and WHR ( p<0.0005) and decrease in glucose uptake due to a reduction in glucose storage over the entire range of glucose tolerance ( r=-0.404; p<0.005). No increase in endogenous glucose production (EGP) was seen until patients had manifest diabetes. However, when EGP was expressed relative to fasting insulin concentrations, there was a linear deterioration of basal hepatic insulin sensitivity ( r=-0.514; p<0.005). The AIR followed a bell-shaped curve with an initial rise and subsequent decrease. However, AIR adjusted for insulin sensitivity (disposition index) showed a linear decrease with increasing glucose concentrations ( r=-0.563; p<0.001) starting already in subjects with normal glucose tolerance. There was an inverse correlation between increase in WHR and NEFA and peripheral as well as hepatic insulin sensitivity. Subjects with the genotype combination of CAPN10 consisting of SNP44 TT and SNP43 GG genotypes had significantly lower insulin-stimulated glucose uptake than carriers of the other genotype combinations (5.3+/-0.4 vs 7.2+/-0.4 mg.ffm kg(-1).min(-1).mU.l(-1); p<0.005). CONCLUSIONS/INTERPRETATION We conclude that the pre-diabetic state is characterised by a similar linear deterioration of peripheral and hepatic insulin sensitivity as beta cell function and that variants in the CAPN10 gene modify this relationship. These findings are compatible with a common defect in muscle, liver and beta cells in the pathogenesis of Type 2 diabetes.
Collapse
Affiliation(s)
- D Tripathy
- Wallenberg Laboratory, Department of Endocrinology, Lund University, Sweden
| | | | | | | | | | | |
Collapse
|
44
|
Song Y, Niu T, Manson JE, Kwiatkowski DJ, Liu S. Are variants in the CAPN10 gene related to risk of type 2 diabetes? A quantitative assessment of population and family-based association studies. Am J Hum Genet 2004; 74:208-22. [PMID: 14730479 PMCID: PMC1181919 DOI: 10.1086/381400] [Citation(s) in RCA: 93] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2003] [Accepted: 11/13/2003] [Indexed: 01/21/2023] Open
Abstract
The calpain-10 gene (CAPN10) on chromosome 2q37.3 was the first candidate gene for type 2 diabetes (T2D) identified through a genomewide screen and positional cloning. One polymorphism (UCSNP-43: G-->A) and a specific haplotype combination defined by three polymorphisms (UCSNP-43, -19, and -63) were linked to an increased risk of T2D in several populations. To quantitatively assess the collective evidence for the effects of CAPN10 on risk of T2D, we conducted a meta-analysis of both population-based and family-based association studies. We retrieved data from the MEDLINE, PubMed, and Online Mendelian Inheritance in Man databases, as well as from other relevant reports and abstracts published up to July 2003. From a total of 26 studies with primary data (21 population-based studies: 5,013 cases and 5,876 controls; 5 family-based studies: 487 parent-offspring trios), we developed a summary database that contains variables of study design, study population/ethnicity, specific polymorphisms and haplotype combinations in CAPN10, and diabetes-related metabolic phenotypes. For population-based studies, we used both fixed-effects and random-effects models to calculate the pooled odds ratio (OR) and 95% confidence interval (CI) for the associations of CAPN10 genotypes with the risk of T2D. We also calculated weighted mean differences for the associations between CAPN10 and diabetes-related quantitative traits. Under either an additive or a dominant effect model, we found no statistically significant relation between CAPN10 genotypes in the UCSNP-43 locus and T2D risk. However, under a recessive model, individuals homozygous for the common G allele had a statistically significant 19% higher risk of T2D than carriers of the A allele (OR 1.19; 95% CI 1.07-1.33). The association between the 112/121 haplotype combination and T2D risk appeared to be overestimated by several initial small studies with positive findings (OR 1.38; 95% CI 1.04-1.84). After we removed these initial studies, this association became nonsignificant (OR 1.11; 95% CI 0.91-1.35). Moreover, we found no evidence for the associations between the UCSNP-43 G/G genotype and the 112/121 haplotype combination and metabolic phenotypes. Our meta-analysis of family-based studies showed only an overtransmission of the rare allele C in UCSNP-44 from heterozygous parents to their affected offspring with T2D. Our analysis indicates that inadequate statistical power, racial/ethnic differences in frequencies of alleles, haplotypes and haplotype combinations, potential gene-gene or gene-environment interactions, publication bias, and multiple hypothesis testing may contribute to the significant heterogeneity in previous studies of CAPN10 and T2D. Our findings also suggest that both large-scale, well-designed association studies and functional studies are warranted to either reliably confirm or conclusively refute the initial hypothesis regarding the role of CAPN10 in T2D risk.
Collapse
Affiliation(s)
- Yiqing Song
- Division of Preventive Medicine and Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital; Department of Epidemiology, Harvard School of Public Health; and Harvard Partners Center for Genetics and Genomics and Hematology Division, Department of Medicine, Brigham and Women’s Hospital, Boston
| | - Tianhua Niu
- Division of Preventive Medicine and Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital; Department of Epidemiology, Harvard School of Public Health; and Harvard Partners Center for Genetics and Genomics and Hematology Division, Department of Medicine, Brigham and Women’s Hospital, Boston
| | - JoAnn E. Manson
- Division of Preventive Medicine and Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital; Department of Epidemiology, Harvard School of Public Health; and Harvard Partners Center for Genetics and Genomics and Hematology Division, Department of Medicine, Brigham and Women’s Hospital, Boston
| | - David J. Kwiatkowski
- Division of Preventive Medicine and Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital; Department of Epidemiology, Harvard School of Public Health; and Harvard Partners Center for Genetics and Genomics and Hematology Division, Department of Medicine, Brigham and Women’s Hospital, Boston
| | - Simin Liu
- Division of Preventive Medicine and Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital; Department of Epidemiology, Harvard School of Public Health; and Harvard Partners Center for Genetics and Genomics and Hematology Division, Department of Medicine, Brigham and Women’s Hospital, Boston
| |
Collapse
|
45
|
Abstract
The follow-up studies to the original report of association of variation at calpain 10 (CAPN10) with type 2 diabetes in the Mexican-American population of Starr County, Texas, encompass a broad range of science. There are association studies on genetic variation at CAPN10 in different human populations over a range of phenotypes related to type 2 diabetes, physiological studies on the biological functions of calpain proteases, and evolutionary studies on CAPN10 and the NIDDM1 region. We review here the studies published to date on CAPN10, as well as the latest findings from positional cloning studies on a number of other complex disorders. Collectively, these studies provide perspective on the challenges of moving from the linkage mapping and positional cloning studies on which we have been focused to an understanding of the biology shaping the relationship of genotype to phenotype at loci influencing susceptibility to complex disorders like type 2 diabetes.
Collapse
Affiliation(s)
- Nancy J Cox
- Department of Human Genetics, the University of Chicago, Chicago, Illinois 60637, USA.
| | | | | | | | | |
Collapse
|
46
|
Weedon MN, Schwarz PEH, Horikawa Y, Iwasaki N, Illig T, Holle R, Rathmann W, Selisko T, Schulze J, Owen KR, Evans J, del Bosque-Plata L, Hitman G, Walker M, Levy JC, Sampson M, Bell GI, McCarthy MI, Hattersley AT, Frayling TM. Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. Am J Hum Genet 2003; 73:1208-12. [PMID: 14574648 PMCID: PMC1180500 DOI: 10.1086/379285] [Citation(s) in RCA: 141] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Affiliation(s)
- Michael N. Weedon
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Peter E. H. Schwarz
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Yukio Horikawa
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Naoko Iwasaki
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Thomas Illig
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Rolf Holle
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Wolfgang Rathmann
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Thomas Selisko
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Jan Schulze
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Katherine R. Owen
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Julie Evans
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Laura del Bosque-Plata
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Graham Hitman
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Mark Walker
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Jonathan C. Levy
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Mike Sampson
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Graeme I. Bell
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Mark I. McCarthy
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Andrew T. Hattersley
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| | - Timothy M. Frayling
- Department of Diabetes Research & Vascular Medicine, Peninsula Medical School, Exeter; Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl-Gustav-Carus of the Technical University, Dresden; Department of Cell Biology, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan; Diabetes Center, Tokyo Women’s Medical University, Tokyo; GSF National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg; GSF National Research Center for Environment and Health, Institute of Health Economics and Health Care Management, Neuherberg; German Diabetes Research Institute, Department of Biometrics and Epidemiology, Düsseldorf; Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago; Department of Diabetes & Metabolic Medicine, Barts and the London, Queen Mary School of Medicine and Dentistry, University of London, London; Department of Medicine, School of Medicine, Newcastle upon Tyne; The Diabetes Research Laboratories, Radcliffe Infirmary, University of Oxford, Oxford; Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford; and Diabetes Centre, Norwich, United Kingdom
| |
Collapse
|
47
|
Gonzalez A, Abril E, Roca A, Aragón MJ, Figueroa MJ, Velarde P, Ruiz R, Fayez O, Galán JJ, Herreros JA, Real LM, Ruiz A. Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients. J Clin Endocrinol Metab 2003; 88:5529-36. [PMID: 14602801 DOI: 10.1210/jc.2003-030322] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Recently, several research groups have evaluated CAPN10 gene in polycystic ovarian syndrome (PCOS) patients and other phenotypes, including hirsutism or intermediate phenotypes of PCOS. Molecular genetic analysis of CAPN10 gene indicates that different alleles may play a role in PCOS susceptibility and could be associated with idiopathic hirsutism. However, these observations are not exempt from controversy, because independent studies cannot replicate these preliminary findings. We present a haplotype-phenotype correlation study of CAPN10 haplotypes in 148 women showing ecographically detected polycystic ovaries (PCO) combined with one or more of these clinical symptoms: amenorrhea or severe oligomenorrhea, hyperandrogenism, and anovulatory infertility, as well as 93 unrelated controls. We have reconstructed and analyzed 482 CAPN10 haplotypes in patients and controls. We detected the association of UCSNP-44 allele with PCO phenotype in the Spanish population (P = 0.02). In addition, we identified several CAPN10 alleles associated to phenotypic differences observed between PCO patients, such as the presence of hypercholesterolemia (haplotype 1121, P = 0.005), presence of hyperandrogenic features (P = 0.05), and familial cancer incidence (haplotype 1111, P = 0.0005). Our results confirm the association of UCSNP-44 allele with PCO phenotype in the Spanish population. Moreover, we have identified novel candidate risk alleles and genotypes, within CAPN10 gene, that could be associated with important phenotypic and prognosis differences observed in PCOS patients.
Collapse
Affiliation(s)
- Alejandro Gonzalez
- Centro Avanzado de Fertilidad, Unidad de Reproducción y Genética Humana, Instituto Medico Serman, 11405 Jerez de la Frontera, Cádiz, Spain.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Shima Y, Nakanishi K, Odawara M, Kobayashi T, Ohta H. Association of the SNP-19 genotype 22 in the calpain-10 gene with elevated body mass index and hemoglobin A1c levels in Japanese. Clin Chim Acta 2003; 336:89-96. [PMID: 14500039 DOI: 10.1016/s0009-8981(03)00320-6] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
BACKGROUND An association of variations in the calpain-10 gene (CAPN10) with type 2 diabetes was originally reported in Mexican Americans. However, some studies in other racial groups were contradictory. METHODS We studied the influence of genotypes and haplotype combinations (haplogenotypes) of CAPN10 on the metabolic traits in 286 Japanese subjects who visited a General Health Check-up Center. RESULTS As for single nucleotide polymorphism (SNP)-19, subjects with genotype 22 had higher body mass index (BMI) and hemoglobin A(1c) (HbA(1c)) levels than those with genotypes 11 and 12 (p=0.003 and p=0.024, respectively). In SNP-63, subjects with genotype 11 had higher BMI and HbA(1c) levels than those with genotypes 12 and 22 (p=0.003 and p=0.045, respectively). Subjects who had genotype 22 at SNP-19 always had genotype 11 at SNP-63. Subjects with haplogenotype 121/121 had higher BMI levels (p=0.021) and tended to have higher HbA(1c) levels (p=0.08) than those with other haplogenotypes. All things considered, SNP-19 genotype 22, which was composed of haplogenotype 121/121 and 121/221, had highest significance level of association with elevated HbA(1c) levels. SNP-43 did not affect metabolic traits in our subjects. Subjects with haplogenotype 112/121 rather showed lower BMI and HbA(1c) levels (p=0.016 and p=0.008) than those with all other haplogenotypes. CONCLUSIONS These results indicate the contribution of SNP-19 in CAPN10 to mild obesity and glucose intolerance in Japanese.
Collapse
Affiliation(s)
- Yukio Shima
- Laboratory of Biochemistry, Kyorin University School of Health Sciences, 476 Miyashita-machi, Hachioji, Tokyo 192-8508, Japan.
| | | | | | | | | |
Collapse
|
49
|
Barroso I, Luan J, Middelberg RPS, Harding AH, Franks PW, Jakes RW, Clayton D, Schafer AJ, O'Rahilly S, Wareham NJ. Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action. PLoS Biol 2003; 1:E20. [PMID: 14551916 PMCID: PMC212698 DOI: 10.1371/journal.pbio.0000020] [Citation(s) in RCA: 226] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2003] [Accepted: 08/08/2003] [Indexed: 01/24/2023] Open
Abstract
Type 2 diabetes is an increasingly common, serious metabolic disorder with a substantial inherited component. It is characterised by defects in both insulin secretion and action. Progress in identification of specific genetic variants predisposing to the disease has been limited. To complement ongoing positional cloning efforts, we have undertaken a large-scale candidate gene association study. We examined 152 SNPs in 71 candidate genes for association with diabetes status and related phenotypes in 2,134 Caucasians in a case-control study and an independent quantitative trait (QT) cohort in the United Kingdom. Polymorphisms in five of 15 genes (33%) encoding molecules known to primarily influence pancreatic beta-cell function-ABCC8 (sulphonylurea receptor), KCNJ11 (KIR6.2), SLC2A2 (GLUT2), HNF4A (HNF4alpha), and INS (insulin)-significantly altered disease risk, and in three genes, the risk allele, haplotype, or both had a biologically consistent effect on a relevant physiological trait in the QT study. We examined 35 genes predicted to have their major influence on insulin action, and three (9%)-INSR, PIK3R1, and SOS1-showed significant associations with diabetes. These results confirm the genetic complexity of Type 2 diabetes and provide evidence that common variants in genes influencing pancreatic beta-cell function may make a significant contribution to the inherited component of this disease. This study additionally demonstrates that the systematic examination of panels of biological candidate genes in large, well-characterised populations can be an effective complement to positional cloning approaches. The absence of large single-gene effects and the detection of multiple small effects accentuate the need for the study of larger populations in order to reliably identify the size of effect we now expect for complex diseases.
Collapse
|
50
|
Reynisdottir I, Thorleifsson G, Benediktsson R, Sigurdsson G, Emilsson V, Einarsdottir AS, Hjorleifsdottir EE, Orlygsdottir GT, Bjornsdottir GT, Saemundsdottir J, Halldorsson S, Hrafnkelsdottir S, Sigurjonsdottir SB, Steinsdottir S, Martin M, Kochan JP, Rhees BK, Grant SFA, Frigge ML, Kong A, Gudnason V, Stefansson K, Gulcher JR. Localization of a susceptibility gene for type 2 diabetes to chromosome 5q34-q35.2. Am J Hum Genet 2003; 73:323-35. [PMID: 12851856 PMCID: PMC1180371 DOI: 10.1086/377139] [Citation(s) in RCA: 151] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2003] [Accepted: 05/21/2003] [Indexed: 01/22/2023] Open
Abstract
We report a genomewide linkage study of type 2 diabetes (T2D [MIM 125853]) in the Icelandic population. A list of type 2 diabetics was cross-matched with a computerized genealogical database clustering 763 type 2 diabetics into 227 families. The diabetic patients and their relatives were genotyped with 906 microsatellite markers. A nonparametric multipoint linkage analysis yielded linkage to 5q34-q35.2 (LOD = 2.90, P=1.29 x 10(-4)) in all diabetics. Since obesity, here defined as body mass index (BMI) > or =30 kg/m(2), is a key risk factor for the development of T2D, we studied the data either independently of BMI or by stratifying the patient group as obese (BMI > or =30) or nonobese (BMI <30). A nonparametric multipoint linkage analysis yielded linkage to 5q34-q35.2 (LOD = 3.64, P=2.12 x (10)-5) in the nonobese diabetics. No linkage was observed in this region for the obese diabetics. Linkage analysis conditioning on maternal transmission to the nonobese diabetics resulted in a LOD score of 3.48 (P=3.12 x 10(-5)) in the same region, whereas conditioning on paternal transmission led to a substantial drop in the LOD score. Finally, we observed potential interactions between the 5q locus and two T2D susceptibility loci, previously mapped in other populations.
Collapse
Affiliation(s)
- Inga Reynisdottir
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Gudmar Thorleifsson
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Rafn Benediktsson
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Gunnar Sigurdsson
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Valur Emilsson
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Anna Sigurlin Einarsdottir
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Eyrun Edda Hjorleifsdottir
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Gudbjorg Th. Orlygsdottir
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Gudrun Thora Bjornsdottir
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Jona Saemundsdottir
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Skarphedinn Halldorsson
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Soffia Hrafnkelsdottir
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Steinunn Bjorg Sigurjonsdottir
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Svana Steinsdottir
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Mitchell Martin
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Jarema P. Kochan
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Brian K. Rhees
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Struan F. A. Grant
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Michael L. Frigge
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Augustine Kong
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Vilmundur Gudnason
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Kari Stefansson
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| | - Jeffrey R. Gulcher
- deCODE Genetics, Icelandic Heart Association, and Landspitali-University Hospital, Reykjavik; and Hoffmann-La Roche, Nutley, NJ
| |
Collapse
|